Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
about
Potential use of rapamycin in HIV infectionClinical use of CCR5 inhibitors in HIV and beyondCCR5: From Natural Resistance to a New Anti-HIV Strategy.Hendra and nipah infection: pathology, models and potential therapies.Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patientsReduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsMiddle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.Emerging antiviral drugsHIV Entry and Its Inhibition by Bifunctional Antiviral Proteins
P2860
Q24606795-59C83DDE-8D42-4D31-887A-D6FCED54890FQ35018145-57C735F8-80DE-4BEB-9BB3-90E71949148BQ35260605-A44A37CB-A27C-4794-AA34-7BC97A7159FBQ35658146-F4E49114-75A9-4243-A1BF-E26FDB4ACA1CQ35910232-3A40C468-75C8-438F-AD5B-22986785EB85Q36871711-7228DD8B-41F0-4776-AD0F-15CD1A5B1B84Q37068522-CF1C8BC3-AFAF-49EB-9D0A-DAAE51CC8419Q37421895-7760A364-FE5A-42D2-9E59-07303FD64757Q38684463-13E399AB-F9A0-487C-81F8-5DB34CF3E318Q39303806-6DB2C1A0-36B8-4327-8508-16A59D5B9382Q39454698-A20B10C8-C5C4-4AD4-A977-45EA4184233FQ43280688-ED72162B-E302-4C5D-945F-B69A9FBCC878Q56786308-4C8D8D6D-9C66-4BDE-938D-0606C79E0BE7Q58555325-B23A165F-D1E9-4FDB-9903-91C88D4C8C6E
P2860
Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Rapamycin reduces CCR5 density ...... iciency virus type 1 in vitro.
@ast
Rapamycin reduces CCR5 density ...... iciency virus type 1 in vitro.
@en
type
label
Rapamycin reduces CCR5 density ...... iciency virus type 1 in vitro.
@ast
Rapamycin reduces CCR5 density ...... iciency virus type 1 in vitro.
@en
prefLabel
Rapamycin reduces CCR5 density ...... iciency virus type 1 in vitro.
@ast
Rapamycin reduces CCR5 density ...... iciency virus type 1 in vitro.
@en
P2093
P2860
P356
P1476
Rapamycin reduces CCR5 density ...... iciency virus type 1 in vitro.
@en
P2093
Alonso Heredia
Anthony Devico
Bruce Gilliam
Douty Bamba
Gregory B Melikyan
Olga Latinovic
Robert R Redfield
P2860
P304
P356
10.1128/AAC.01602-06
P407
P50
P577
2007-05-07T00:00:00Z